aura glp 1 GLP-1 Up GLP-1 Advanced Intra-Oral Spray, by
Description
no major safety concerns were observed
I wrote about how this market is evolving in India, why generics will accelerate adoption, and why the winners will be platforms, not prescriptions
We think Novos stock looks slightly overvalued after this announcement.
The FDA significantly increased its compliance activity surrounding advertising for compounded drugs in 2025, and recent remarks from an FDA official highlighted the agencys concerns about claims that state or imply the equivalence of compounded drugs to approved drugs.
